Pre-Clinical Proof of Concept with Oncology Lead

RNS Number : 7027M

Redx Pharma plc

11 May 2015

 

11 May 2015

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

Reaches pre-clinical proof of concept with oncology lead

Redx, the drug discovery and development company, is pleased to announce that it has reached pre-clinical proof of concept stage with an advanced oncology lead which has the potential to tackle hard-to-treat cancers including pancreatic, breast and head and neck cancer.

This represents the fifth program to have advanced through Redx's innovative development pipeline to pre-clinical proof of concept and has been achieved in just over 12 months, from a standing start. Only one other similar treatment exists, which is currently in clinical development.

The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. These are associated with tumorigenesis, metastasis, recurrence and resistance in cancer. It will have the potential to be taken orally by patients as a once daily dose.

Dr Neil Murray, CEO of Redx, said:

"We're very pleased to have reached pre-clinical proof of concept with this very promising program. The cancers it has the potential to tackle are some of the most hard-to-treat. Consequently, we are delighted to be making steps on the journey to address the challenge and to have developed this novel Porcupine inhibitor which will help to tackle these areas of high unmet need.

"Redx's access to primary patient sample and extensive niche expertise in cancer stem cell assays, have proved particularly helpful in this instance. This program also demonstrates Redx's capability to accelerate development timelines - taking a program to proof of concept in just over 12 months from a standing start.  We look forward to continuing to develop our Porcupine assets and assess their potential as a treatment for pancreatic, triple negative breast, and head and neck cancers."

For further information, please contact:

Redx Pharma Plc		T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Shore Capital (Nomad and Broker)		T: 020 7408 4090
Bidhi Bhoma / Patrick Castle / Edward Mansfield
KTZ Communications		T: 020 3178 6378
Katie Tzouliadis

About Redx Pharma Plc

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and infection. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary, (patent-protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain and blood cancers.  

 

END

 

 

MSCSSAFMAFISEFI